Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Mephenytoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mephenytoin SCHEMBL21768 | 1.00 | CYP2C19 (1.00) | CYP2C19TSHRLMNAFPR2TDP1 | |
| Mephenytoin SCHEMBL4778454 | 0.95 | CYP2C19 (0.91) | CYP2C19TSHRLMNAFPR2TDP1 | |
| Phenobarbital SCHEMBL6426618 | 0.87 | CYP2C19 (0.76) | CYP2C19TSHRLMNAFPR2TDP1 | |
| Phenytoin SCHEMBL9834729 | 0.87 | CYP2C19 (0.76) | CYP2C19TSHRLMNAFPR2GAA | |
| Mephenytoin SCHEMBL17396223 | 0.86 | CYP2C19 (0.74) | CYP2C19TSHRLMNAFPR2TDP1 | |
| SCHEMBL28008015 | 0.83 | CYP2C19 (0.71) | CYP2C19TSHRLMNAFPR2GAA | |
| SCHEMBL14067600 | 0.83 | CYP2C19 (0.71) | CYP2C19TSHRLMNAFPR2GAA | |
| SCHEMBL5303102 | 0.83 | CYP2C19 (0.71) | CYP2C19TSHRLMNAFPR2TDP1 | |
| SCHEMBL28794825 | 0.78 | CYP2C19 (1.00) | CYP2C19TSHRLMNATDP1GAA | |
| SCHEMBL29549519 | 0.78 | CYP2C19 (1.00) | CYP2C19TSHRLMNATDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6732 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-20250281477-A1 | TREATMENT OF CNS CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2025-09-11 | — | — | US | claimed |
| US-20250152526-A1 | USES OF IVALTINOSTAT FOR TREATING PANCREATIC CANCER | CG PHARMACEUTICALS, INC | 2025-05-15 | — | — | US | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| EP-4482480-A1 | USES OF IVALTINOSTAT FOR TREATING PANCREATIC CANCER | CG Pharmaceuticals, Inc (US) | 2025-01-01 | — | — | EP | claimed |
| CN-118742302-A | Use of ivastatin for the treatment of cancer | CG制药股份有限公司 | 2024-10-01 | — | — | CN | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| CN-114590005-B | Antibacterial, antiviral and waterproof preparation and application thereof in preparation of protective clothing fabric | 绍兴崇高新材料科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| WO-1989000856-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF BONE-WASTING DISEASES | OSTEOTECH CORPORATION (US) | 1989-02-09 | — | — | WO | claimed |
| EP-0302714-A2 | Pharmaceutical composition for treatment of bone-wasting diseases | OSTEOTECH CORPORATION (US) | 1989-02-08 | — | — | EP | claimed |
| EP-0224283-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-06-03 | — | — | EP | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| US-4657285-A | Tubular rubber products | BRIDGESTONE CORPORATION (JP) | 1987-04-14 | — | — | US | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-4160818-A | Fluorimetric immunoassay for diphenylhydantoin | TECHNICON INSTRUMENTS CORPORATION (US) | 1979-07-10 | — | — | US | claimed |